Dr H Daniel Perez MD
Co-Founder, CEO and Chairman
H Daniel Perez MD co-founded Naia Limited and currently serves as chairman and chief executive officer.
Prior to that, he was a venture partner at Bay City Capital. Earlier in his career, he was president and chief executive officer of Berlex Biosciences (the U.S. arm of Schering AG). He led R&D efforts in the United States, Berlin and Kobe, initiated multiple clinical trials, and oversaw the execution of numerous collaborations, licensing deals, spin-outs and acquisitions until he left the company upon its acquisition by Bayer. Dr. Perez has published extensively and has been elected to multiple scientific societies and nominated to the National Academy of Sciences.
Dr. Perez serves on the Board of Directors of Presidio Pharmaceuticals and Celtaxsys, on the Scientific Advisory Board of Cardium, on the Investment Board of Glaxo GSK, China and on the President’s Council for the Gladstone Institutes at the University of California, San Francisco (UCSF). Previously, he was a member of the Board of Directors of BayBio, Cleveland Biolabs and Hyperion Therapeutics.
He received his medical degree in Buenos Aires, Argentina. He completed his medical training at Beth Israel-Mount Sinai in New York and a fellowship in rheumatology and immunology at New York University. He served on the faculty at New York University as an assistant professor of medicine and at UCSF as a professor of medicine before joining the pharmaceutical industry.